This company has been acquired
Vigil Neuroscience Management
Management criteria checks 4/4
Vigil Neuroscience's CEO is Ivana Magovcevic-Liebisch, appointed in Jul 2020, has a tenure of 5.08 years. total yearly compensation is $2.63M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $1.79M. The average tenure of the management team and the board of directors is 3.6 years and 3.7 years respectively.
Key information
Ivana Magovcevic-Liebisch
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 23.54% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 3.6yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact
Jun 05Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?
Feb 05
Vigil: Now A 'Hold' Based On Two New Pipeline Developments
Jan 23Vigil Neuroscience: Down On A Competitor's Failure
Dec 03We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully
Oct 17We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate
May 30Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Feb 01Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Oct 14Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Jun 27Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Mar 14Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation
Nov 29Vigil draws bullish view at Wedbush on upcoming readout for lead asset
Sep 16Vigil Neuroscience announces $75M PIPE financing
Aug 12We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely
Jul 25Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?
Apr 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$92m |
| Mar 31 2025 | n/a | n/a | -US$87m |
| Dec 31 2024 | US$3m | US$620k | -US$84m |
| Sep 30 2024 | n/a | n/a | -US$83m |
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$83m |
| Dec 31 2023 | US$4m | US$585k | -US$83m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$76m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$4m | US$557k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$63m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$50m |
| Dec 31 2021 | US$3m | US$450k | -US$43m |
| Dec 31 2020 | US$3m | US$204k | -US$57m |
Compensation vs Market: Ivana's total compensation ($USD2.63M) is about average for companies of similar size in the US market ($USD2.56M).
Compensation vs Earnings: Ivana's compensation has been consistent with company performance over the past year.
CEO
Ivana Magovcevic-Liebisch (58 yo)
Dr. Ivana Magovcevic-Liebisch, Ph. D., J. D., serves as Independent Director of Quanterix Corporation since October 2, 2024. She serves as an Independent Director of Acrivon Therapeutics, Inc. since Februa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$2.63m | 0.47% $ 1.8m | |
| Chief Financial Officer | 4.4yrs | US$1.25m | 0.0084% $ 32.2k | |
| Chief Medical Officer | 1.4yrs | US$1.37m | 0% $ 0 | |
| Senior Director of Facilities & Operations | 2.6yrs | no data | no data | |
| Chief Scientific Officer | 2.5yrs | US$2.77m | no data | |
| Senior Manager of Information Technology | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| VP & Head of Corporate Development | 3.6yrs | no data | no data | |
| Senior Human Resources Associate | no data | no data | no data | |
| Senior VP & Head of Early Development | 4.9yrs | no data | no data | |
| Senior VP & Head of Neuroimmunology | 3.6yrs | no data | no data | |
| Senior Vice President of Strategic Operations | 3.6yrs | no data | no data |
Experienced Management: VIGL's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$2.63m | 0.47% $ 1.8m | |
| Independent Director | 3.1yrs | US$116.79k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$116.44k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$119.94k | 0% $ 0 | |
| Independent Chairman of the Board | 5.2yrs | US$143.73k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.1yrs | US$102.45k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 4yrs | US$99.06k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$123.84k | 0.025% $ 96.7k | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
Experienced Board: VIGL's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/06 00:11 |
| End of Day Share Price | 2025/08/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vigil Neuroscience, Inc. is covered by 4 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |
| Myles Minter | William Blair & Company L.L.C. |